Corcept Therapeutics shares are trading higher after Canaccord Genuity maintained a Buy rating on the stock and raised its price target from $38 to $78.
Portfolio Pulse from Benzinga Newsdesk
Corcept Therapeutics shares are trading higher after Canaccord Genuity maintained a Buy rating on the stock and raised its price target from $38 to $78.
July 31, 2024 | 4:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Corcept Therapeutics shares are trading higher after Canaccord Genuity maintained a Buy rating on the stock and raised its price target from $38 to $78.
The positive analyst rating and significant increase in the price target from $38 to $78 by Canaccord Genuity are likely to boost investor confidence and drive the stock price higher in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100